SG11202100348SA - Oligonucleotides for modulating rtel1 expression - Google Patents
Oligonucleotides for modulating rtel1 expressionInfo
- Publication number
- SG11202100348SA SG11202100348SA SG11202100348SA SG11202100348SA SG11202100348SA SG 11202100348S A SG11202100348S A SG 11202100348SA SG 11202100348S A SG11202100348S A SG 11202100348SA SG 11202100348S A SG11202100348S A SG 11202100348SA SG 11202100348S A SG11202100348S A SG 11202100348SA
- Authority
- SG
- Singapore
- Prior art keywords
- oligonucleotides
- modulating
- rtel1
- expression
- rtel1 expression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18183477 | 2018-07-13 | ||
| PCT/EP2019/068639 WO2020011902A1 (en) | 2018-07-13 | 2019-07-11 | Oligonucleotides for modulating rtel1 expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202100348SA true SG11202100348SA (en) | 2021-02-25 |
Family
ID=62951968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202100348SA SG11202100348SA (en) | 2018-07-13 | 2019-07-11 | Oligonucleotides for modulating rtel1 expression |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210147850A1 (zh) |
| EP (1) | EP3821013A1 (zh) |
| JP (1) | JP2021524277A (zh) |
| KR (1) | KR20210033004A (zh) |
| CN (1) | CN112534055A (zh) |
| AU (1) | AU2019300324A1 (zh) |
| BR (1) | BR112021000538A2 (zh) |
| CA (1) | CA3106288A1 (zh) |
| CL (1) | CL2021000018A1 (zh) |
| CR (1) | CR20210015A (zh) |
| IL (1) | IL279929A (zh) |
| MX (1) | MX2021000404A (zh) |
| PE (1) | PE20211306A1 (zh) |
| SG (1) | SG11202100348SA (zh) |
| TW (1) | TWI791868B (zh) |
| WO (1) | WO2020011902A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202246500A (zh) | 2021-02-02 | 2022-12-01 | 瑞士商赫孚孟拉羅股份公司 | 用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸 |
| WO2023111210A1 (en) | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Combination of oligonucleotides for modulating rtel1 and fubp1 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE239484T1 (de) | 1991-10-24 | 2003-05-15 | Isis Pharmaceuticals Inc | Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| CN1273476C (zh) | 1997-09-12 | 2006-09-06 | 埃克西康有限公司 | 寡核苷酸类似物 |
| ES2234563T5 (es) | 1999-02-12 | 2018-01-17 | Daiichi Sankyo Company, Limited | Nuevos análogos de nucleósidos y oligonucleótidos |
| NZ514348A (en) | 1999-05-04 | 2004-05-28 | Exiqon As | L-ribo-LNA analogues |
| US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
| US7393950B2 (en) * | 2002-08-29 | 2008-07-01 | Hong Kong University Of Science & Technology | Antisense oligonucleotides targeted to human CDC45 |
| EP1569661B1 (en) | 2002-11-18 | 2009-09-09 | Santaris Pharma A/S | Antisense design |
| AU2004221760B2 (en) | 2003-03-21 | 2010-03-18 | Roche Innovation Center Copenhagen A/S | Short interfering RNA (siRNA) analogues |
| BRPI0411219A (pt) | 2003-06-12 | 2006-07-18 | Nucleonics Inc | seqüências de hbv e hcv conservadas úteis para silenciamento de gene |
| US20090221679A1 (en) | 2005-08-10 | 2009-09-03 | Amy Espeseth | Novel HIV Targets |
| WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| JP2009524419A (ja) | 2006-01-27 | 2009-07-02 | サンタリス ファーマ アー／エス | Ｌｎａ修飾したホスホロチオール化オリゴヌクレオチド |
| PL2314594T3 (pl) | 2006-01-27 | 2014-12-31 | Isis Pharmaceuticals Inc | Zmodyfikowane w pozycji 6 analogi bicykliczne kwasów nukleinowych |
| EP2002004B1 (en) | 2006-03-23 | 2015-10-14 | Roche Innovation Center Copenhagen A/S | Small internally segmented interfering rna |
| US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
| DK2066684T3 (da) | 2006-05-11 | 2012-10-22 | Isis Pharmaceuticals Inc | 5´-Modificerede bicycliske nukleinsyreanaloge |
| ES2388590T3 (es) | 2007-05-30 | 2012-10-16 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos con puente aminometileno N-sustituido. |
| ES2386492T3 (es) | 2007-06-08 | 2012-08-21 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos carbocíclicos |
| ES2376507T5 (es) | 2007-07-05 | 2015-08-31 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos 6-disustituidos |
| US8546556B2 (en) | 2007-11-21 | 2013-10-01 | Isis Pharmaceuticals, Inc | Carbocyclic alpha-L-bicyclic nucleic acid analogs |
| EP2356129B1 (en) | 2008-09-24 | 2013-04-03 | Isis Pharmaceuticals, Inc. | Substituted alpha-l-bicyclic nucleosides |
| US20100249214A1 (en) | 2009-02-11 | 2010-09-30 | Dicerna Pharmaceuticals | Multiplex dicer substrate rna interference molecules having joining sequences |
| CA3151965A1 (en) | 2008-12-18 | 2010-07-15 | Dicerna Pharmaceuticals, Inc. | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
| US9012421B2 (en) | 2009-08-06 | 2015-04-21 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
| WO2011156202A1 (en) | 2010-06-08 | 2011-12-15 | Isis Pharmaceuticals, Inc. | Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
| KR102072631B1 (ko) | 2010-08-17 | 2020-02-03 | 시르나 쎄러퓨틱스 인코퍼레이티드 | 짧은 간섭 핵산 （ｓｉＮＡ）을 사용한 Ｂ형 간염 바이러스 （ＨＢＶ） 유전자 발현의 ＲＮＡ 간섭 매개 억제 |
| PL3124610T3 (pl) | 2010-10-28 | 2019-09-30 | Benitec Biopharma Limited | Leczenie hbv |
| RU2667524C2 (ru) | 2011-04-21 | 2018-09-21 | Ионис Фармасьютикалз, Инк. | Модулирование экспрессии вируса гепатита b (hbv) |
| CN113430196A (zh) | 2011-06-30 | 2021-09-24 | 箭头药业股份有限公司 | 用于抑制乙型肝炎病毒的基因表达的组合物和方法 |
| WO2013022967A1 (en) | 2011-08-11 | 2013-02-14 | Isis Pharmaceuticals, Inc. | Gapped oligomeric compounds comprising 5'-modified deoxyribonucleosides in the gap and uses thereof |
| EP3453761A1 (en) | 2011-08-29 | 2019-03-13 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
| WO2013154798A1 (en) | 2012-04-09 | 2013-10-17 | Isis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
| WO2013159109A1 (en) | 2012-04-20 | 2013-10-24 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis b virus (hbv) expression |
| MY173826A (en) | 2012-11-15 | 2020-02-24 | Roche Innovation Ct Copenhagen As | Oligonucleotide conjugates |
| IL284593B2 (en) | 2013-05-01 | 2023-02-01 | Ionis Pharmaceuticals Inc | Compositions and methods for modulation of hbv and ttr expression |
| US20160138114A1 (en) * | 2013-06-19 | 2016-05-19 | The Regents Of The University Of California | Biomarkers of Response to Inhibition of Poly-ADP Ribose Polymerase (PARP) in Cancer |
| CN112263682A (zh) | 2013-06-27 | 2021-01-26 | 罗氏创新中心哥本哈根有限公司 | 靶向pcsk9的反义寡聚体和缀合物 |
| WO2015113922A1 (en) | 2014-01-30 | 2015-08-06 | Roche Innovation Center Copenhagen A/S | Poly oligomer compound with biocleavable conjugates |
| GB201408623D0 (en) | 2014-05-15 | 2014-07-02 | Santaris Pharma As | Oligomers and oligomer conjugates |
| AU2015329974B2 (en) | 2014-10-10 | 2019-06-20 | F. Hoffmann-La Roche Ag | GaINAc phosphoramidites, nucleic acid conjugates thereof and their use |
| CN108136206B (zh) | 2015-07-17 | 2021-10-15 | 阿克丘勒斯治疗公司 | 抗乙型肝炎病毒的组合物和药剂及其用途 |
| CA2991639A1 (en) | 2015-08-07 | 2017-02-16 | Arrowhead Pharmaceuticals, Inc. | Rnai therapy for hepatitis b virus infection |
| MA45496A (fr) | 2016-06-17 | 2019-04-24 | Hoffmann La Roche | Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b |
| CA3044598A1 (en) | 2016-11-23 | 2018-05-31 | Alnylam Pharmaceuticals, Inc. | Modified rna agents with reduced off-target effect |
-
2019
- 2019-07-11 AU AU2019300324A patent/AU2019300324A1/en not_active Abandoned
- 2019-07-11 JP JP2021500833A patent/JP2021524277A/ja active Pending
- 2019-07-11 CR CR20210015A patent/CR20210015A/es unknown
- 2019-07-11 BR BR112021000538-2A patent/BR112021000538A2/pt unknown
- 2019-07-11 PE PE2020002231A patent/PE20211306A1/es unknown
- 2019-07-11 WO PCT/EP2019/068639 patent/WO2020011902A1/en unknown
- 2019-07-11 CN CN201980047097.2A patent/CN112534055A/zh active Pending
- 2019-07-11 KR KR1020217004297A patent/KR20210033004A/ko not_active Application Discontinuation
- 2019-07-11 CA CA3106288A patent/CA3106288A1/en active Pending
- 2019-07-11 EP EP19739971.0A patent/EP3821013A1/en active Pending
- 2019-07-11 MX MX2021000404A patent/MX2021000404A/es unknown
- 2019-07-11 SG SG11202100348SA patent/SG11202100348SA/en unknown
- 2019-07-12 TW TW108124604A patent/TWI791868B/zh active
-
2021
- 2021-01-03 IL IL279929A patent/IL279929A/en unknown
- 2021-01-05 CL CL2021000018A patent/CL2021000018A1/es unknown
- 2021-01-13 US US17/147,797 patent/US20210147850A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI791868B (zh) | 2023-02-11 |
| WO2020011902A1 (en) | 2020-01-16 |
| MX2021000404A (es) | 2021-03-25 |
| TW202020152A (zh) | 2020-06-01 |
| CR20210015A (es) | 2021-03-22 |
| CA3106288A1 (en) | 2020-01-16 |
| KR20210033004A (ko) | 2021-03-25 |
| EP3821013A1 (en) | 2021-05-19 |
| AU2019300324A1 (en) | 2021-01-21 |
| CL2021000018A1 (es) | 2021-07-09 |
| PE20211306A1 (es) | 2021-07-20 |
| BR112021000538A2 (pt) | 2021-04-06 |
| IL279929A (en) | 2021-03-01 |
| CN112534055A (zh) | 2021-03-19 |
| JP2021524277A (ja) | 2021-09-13 |
| US20210147850A1 (en) | 2021-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202007542B (en) | Oligonucleotides for modulating scn9a expression | |
| SG11201911704UA (en) | Antisense oligonucleotides for modulating the function of a t cell | |
| RS64073B1 (sr) | Modulatori tmem16a | |
| ZA201808291B (en) | Antisense oligonucleotides for modulating htra1 expression | |
| IL279056A (en) | Oligonucleotides for modulation of tau expression | |
| GB2594008B (en) | Modulators | |
| IL276357A (en) | Oligonucleotides to modulate TMEM106B expression | |
| GB201908106D0 (en) | No details | |
| IL271039A (en) | Antisense oligonucleotides regulate htra1 expression | |
| IL279929A (en) | Oligonucleotides to modulate RTEL1 expression | |
| EP4041248A4 (en) | MODIFIED OLIGONUCLEOTIDES | |
| GB201905867D0 (en) | No details | |
| IL282731A (en) | Organogulfonic compounds | |
| GB2585587B (en) | Modulators | |
| EP3819231C0 (en) | APPLICATION CONTAINER | |
| GB201714330D0 (en) | Oligonucleotides | |
| GB201608907D0 (en) | Means for modulating gene expression | |
| GB201918974D0 (en) | Gpr52 modulator compounds | |
| GB201918992D0 (en) | GPR52 modulator compounds | |
| GB201916298D0 (en) | GPR52 modulator compounds | |
| SG11202011746UA (en) | Application container | |
| ZA201905705B (en) | Dispensing arrangement | |
| GB201904663D0 (en) | No details | |
| GB201813574D0 (en) | A1 | |
| GB201809804D0 (en) | No details |